FR2838649B1 - Composition anti-vih, procede de fabrication et medicament - Google Patents

Composition anti-vih, procede de fabrication et medicament

Info

Publication number
FR2838649B1
FR2838649B1 FR0204926A FR0204926A FR2838649B1 FR 2838649 B1 FR2838649 B1 FR 2838649B1 FR 0204926 A FR0204926 A FR 0204926A FR 0204926 A FR0204926 A FR 0204926A FR 2838649 B1 FR2838649 B1 FR 2838649B1
Authority
FR
France
Prior art keywords
manufacture
medicinal product
hiv composition
composition
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0204926A
Other languages
English (en)
Other versions
FR2838649A1 (fr
Inventor
Romain Vives
Quentin Sattentau
Claudio Vita
Jacob Hugues Lortat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Original Assignee
Centre National de la Recherche Scientifique CNRS
Commissariat a lEnergie Atomique CEA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0204926A priority Critical patent/FR2838649B1/fr
Application filed by Centre National de la Recherche Scientifique CNRS, Commissariat a lEnergie Atomique CEA filed Critical Centre National de la Recherche Scientifique CNRS
Priority to CA2481325A priority patent/CA2481325C/fr
Priority to US10/509,686 priority patent/US7494975B2/en
Priority to AU2003246840A priority patent/AU2003246840A1/en
Priority to JP2003585751A priority patent/JP5004408B2/ja
Priority to PCT/FR2003/001234 priority patent/WO2003089000A2/fr
Priority to EP03746844A priority patent/EP1496932A2/fr
Publication of FR2838649A1 publication Critical patent/FR2838649A1/fr
Application granted granted Critical
Publication of FR2838649B1 publication Critical patent/FR2838649B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FR0204926A 2002-04-19 2002-04-19 Composition anti-vih, procede de fabrication et medicament Expired - Fee Related FR2838649B1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
FR0204926A FR2838649B1 (fr) 2002-04-19 2002-04-19 Composition anti-vih, procede de fabrication et medicament
US10/509,686 US7494975B2 (en) 2002-04-19 2003-04-17 Anti-HIV composition, production method thereof and medicament
AU2003246840A AU2003246840A1 (en) 2002-04-19 2003-04-17 Anti-hiv composition, production method thereof and medicament
JP2003585751A JP5004408B2 (ja) 2002-04-19 2003-04-17 抗ｈｉｖ組成物、その製造方法及び医薬
CA2481325A CA2481325C (fr) 2002-04-19 2003-04-17 Composition anti-vih, comprenant un polyanion et un agent agissant sur gp120 de acon equivalent au cd4
PCT/FR2003/001234 WO2003089000A2 (fr) 2002-04-19 2003-04-17 Composition anti-vih, comprenant un polyanion et un agent agissant sur gp120 de acon equivalent au cd4
EP03746844A EP1496932A2 (fr) 2002-04-19 2003-04-17 Composition anti-vih, procede de fabrication et medicament.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0204926A FR2838649B1 (fr) 2002-04-19 2002-04-19 Composition anti-vih, procede de fabrication et medicament

Publications (2)

Publication Number Publication Date
FR2838649A1 FR2838649A1 (fr) 2003-10-24
FR2838649B1 true FR2838649B1 (fr) 2006-01-13

Family

ID=28686195

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0204926A Expired - Fee Related FR2838649B1 (fr) 2002-04-19 2002-04-19 Composition anti-vih, procede de fabrication et medicament

Country Status (7)

Country Link
US (1) US7494975B2 (fr)
EP (1) EP1496932A2 (fr)
JP (1) JP5004408B2 (fr)
AU (1) AU2003246840A1 (fr)
CA (1) CA2481325C (fr)
FR (1) FR2838649B1 (fr)
WO (1) WO2003089000A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007144685A1 (fr) * 2006-06-13 2007-12-21 Commissariat A L'energie Atomique Peptides mimétiques du cd4 et utilisations de ceux-ci
FR2904627B1 (fr) * 2006-08-04 2008-11-07 Pasteur Institut Nouveaux peptides actives, purifies et isoles, derives du recepteur cd4 (mini-cd4) et leur procece de preparation
EP2087911A1 (fr) * 2008-02-06 2009-08-12 Institut Pasteur Molécules conjuguées comprenant un peptide dérivé du récepteur CD4 couplé à un polyanion pour le traitement du SIDA
CN108640977A (zh) * 2018-06-18 2018-10-12 上海大学 特异性结合HIV上包膜糖蛋白gp120的多肽及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7544987A (en) * 1986-06-03 1988-01-11 Pert, C.B. Small peptides which inhibit binding to t-4 receptors
DE3808353A1 (de) * 1988-03-12 1989-09-21 Basf Ag Kombinationen von polysulfatierten heparinen bei der bekaempfung von retrovirusinfektionen
DE68904264T2 (de) * 1988-08-24 1993-05-27 Akzo Nv Fragmente und fraktionen von heparin mit wirkung gegen hiv.
GB9020872D0 (en) * 1990-09-25 1990-11-07 Ml Lab Plc Pharmaceutical compositions and use thereof
JPH0959178A (ja) * 1995-08-24 1997-03-04 Samu Kenkyusho:Kk 抗ウイルス剤及び抗ウイルス作用増強剤
JPH1029952A (ja) * 1996-07-16 1998-02-03 Takara Shuzo Co Ltd ヒト免疫不全ウイルス感染の制御用組成物および制御方法
FR2819809B1 (fr) * 2001-01-23 2003-05-16 Commissariat Energie Atomique Peptides presentant un affinite pour la proteine virale gp120, et utilisation de ces peptides

Also Published As

Publication number Publication date
WO2003089000A3 (fr) 2004-04-08
CA2481325A1 (fr) 2003-10-30
US20060084593A1 (en) 2006-04-20
CA2481325C (fr) 2011-07-26
AU2003246840A8 (en) 2003-11-03
FR2838649A1 (fr) 2003-10-24
WO2003089000A2 (fr) 2003-10-30
JP2005528405A (ja) 2005-09-22
US7494975B2 (en) 2009-02-24
EP1496932A2 (fr) 2005-01-19
JP5004408B2 (ja) 2012-08-22
AU2003246840A1 (en) 2003-11-03

Similar Documents

Publication Publication Date Title
JP2022031635A5 (fr)
JP2020500538A5 (fr)
CY1115456T1 (el) Μεθοδος χορηγησης αντισωματων αντι-ιl-5
UA90457C2 (ru) Человеческое моноклональное антитело, которое специфически связывается с м-csf человека и блокирует связывание м-csf с с-fms
BRPI0821168B8 (pt) anticorpo isolado que se liga ao il-21 humano, ou um fragmento deste, usos de dito anticorpo ou fragmento, e, hibridoma
HRP20180027T1 (hr) Protutijela za neutraliziranje virusa ljudske imunodeficijencije (hiv)
HRP20120606T4 (hr) Protutijela protiv il-17
JP2017113019A5 (fr)
RU2013105769A (ru) Биологические материалы и их применение
EA201000018A1 (ru) Лиофилизированные лекарственные формы иммуноглобулинов и способы их получения
JP2019504032A5 (fr)
RS52332B (en) HUMAN ANTI-NGF NEUTRAL ANTIBODIES AS SELECTIVE NGF SIGNAL ROUTE INHIBITORS
AR041173A1 (es) Aniticuerpo monoclonal anti- il- 1r1 humano terapeutico
UY28170A1 (es) Preparacion y tratamiento para las enfermedades desmielinizantes y paralisis mediante la aplicacion de agentes remielinizantes.
JP2017531642A5 (fr)
RU2011105062A (ru) Нейтрализующие антитела против вируса гриппа а и их использование
IL259940B2 (en) A method for treating or improving metabolic disorders using gastric inhibitory peptide receptor binding proteins in combination with glucagon-like peptide 1 agonists
HRP20240182T1 (hr) Ljudska monoklonska protutijela za teški akutni respiratorni sindrom koronavirusa 2 (sars-cov-2)
WO2003078468A3 (fr) Utilisation d'une substance active se liant a cd28 pour la preparation d'une composition pharmaceutique
MX2021004779A (es) Anticuerpos cd47 novedosos y metodos para usarlos.
PE20221865A1 (es) Anticuerpos contra el virus de la fiebre amarilla y metodos de su generacion y uso
JP2015501830A5 (fr)
EA200401081A1 (ru) Fab-фрагменты моноклонального антитела человека, направленные против гликопротеина e2 hcv и обладающие нейтрализующей активностью in vitro
PE20230464A1 (es) Union de anticuerpos multiespecificos a bcma
JP2020533382A5 (fr)

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16

PLFP Fee payment

Year of fee payment: 17

PLFP Fee payment

Year of fee payment: 18

ST Notification of lapse

Effective date: 20201205